Closed · RFA-CA-14-501 · CFDA 93.394 · Discretionary
Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN) (U24)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $11.8M
- Award range
- Closed
- Status
- August 15, 2014
- Close date
- 5
- Expected awards
The verdict
Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN) (U24) is a closed discretionary listing from National Institutes of Health that offered Up to $11,750,000 across 5 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $11.8M
- award range
- Closed
- application status
- 5
- expected awards
- 93.394
- CFDA program
Archived opportunity record
Limited Competition: Biospecimen Banks to Sup… is closed (last close August 15, 2014). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed August 15, 2014
Est. Total Funding
$11,750,000
Expected Awards
5
Instrument
Cooperative Agreement
Description
This Funding Opportunity Announcement (FOA) solicits applications from institutions/organizations to establish Biospecimen Banks for the NCI National Clinical Trials Network (NCTN; https://research.usc.edu/nci-national-clinical-trials-network-nctn-program/). The NCTN Biospecimen Banks will be responsible for collecting, storing, and distributing well-annotated human specimens from patients with cancer who are participating in NCI-funded Phase III and large Phase II clinical treatment trials. The goal is to support NCTN with the state-of the-art biospecimen banking infrastructure and operations including maintenance of up-to-date specimen inventory. The NCTN Banks will distribute to qualified investigators the biospecimens linked to high-quality clinical data (including treatment and outcome information) that are critical for developing and validating biomarkers for cancer diagnosis, prognosis and prediction of responses to therapy. The NCTN Banks will work in collaboration with NCTN Groups and Group Statistical and Data Management Centers to ensure effective operation. One of the NCTN banks will be also expected to provide banking services for the NCI Experimental Therapeutics Clinical Trials Network (ETCTN; http://ctep.cancer.gov/initiativesPrograms/etctn.htm/). ETCTN collects biospecimens from cancer patients treated on NCI Phase I and small Phase II clinical trials).
Catch-all / unrestricted eligibility mark · RFA-CA-14-501
Grants.gov marks Limited Competition: Biospecimen Banks to Sup… with a catch-all / unrestricted eligibility code (Others (see official listing text)). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). Only 187 other National Institutes of Health listings share this exact eligibility-code string (2% of 12,420).
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Limited Competition: Biospecimen Banks to Sup… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.394 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |